Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIB4920 + tumor necrosis factor inhibitor
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
This is a combination therapy consisting of VIB4920 (also known as dazodalibep or MEDI4920) and a tumor necrosis factor (TNF) inhibitor. VIB4920 is a recombinant fusion protein engineered to antagonize CD40 ligand (CD40L), thereby inhibiting the CD40/CD40L pathway, which plays a critical role in T-cell and B-cell interactions and immune activation. It is designed to reduce autoimmune activity by blocking this co-stimulatory signal without causing adverse haemostasis seen with earlier anti-CD40L agents[2][4][5]. TNF inhibitors are biologic drugs that suppress the pro-inflammatory cytokine TNF-alpha, widely used in autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, and others[6][9]. The combination aims to provide dual immunomodulation by targeting both T/B cell co-stimulation (via CD40L blockade) and inflammatory cytokine signaling (via TNF inhibition). This approach may be investigated for enhanced efficacy in treating autoimmune diseases.
- Other names
- dazodalibep + tumor necrosis factor inhibitorMEDI4920 + tumor necrosis factor inhibitor
02
Targets
CD40LG (CD40 ligand extracellular domain)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on VIB4920 + tumor necrosis factor inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIB4920 + tumor necrosis factor inhibitor.